Antagonists & Inhibitors

Ionotropic Glutamate Receptors Blocker
NMDA Receptor Antagonists
AP5 (2-amino-5-phosphonopentanoic acid, 5.0 microg)
MK-801 (dizocilpine, an open channel blocker)
DNQX (6,7-dinitroquinoxaline-2,3-dione)
CPP ((+/-)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid)

AMPA Receptor Antagonists
Quinoxalines
CNQX (6-cyano-7-nitroquinoxaline-2,3-(1H,4H)-dione, 0.5 microg)
NBQX (1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide)
DNQX (6,7-dinitroquinoxaline-2,3-dione)
Biarylpropylsulfonamides
LY392098, LY300168, LY303070 etc.

Kainate Receptor Antagonists
Quinoxalines
CNQX (6-cyano-7-nitroquinoxaline-2,3-(1H,4H)-dione, 0.5 microg)
DNQX (6,7-dinitroquinoxaline-2,3-dione)
ATPA (RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl) propanoic acid, GluR-5-selective)

Other Relevant Receptors Blocker
GABA A Receptor Antagonists
Picrotoxin (0.08 microg)

GABA A Receptor-Mediated Inhibition
Muscimol (1 microg/side)

Protein Kinase C Inhibitors
Staurosporin (1.0 microg)

Calcium/Calmodulin Dependent Protein Kinase II Inhibitors
Kn-62 (3.5 ng)

Cholinergic Muscarinic Receptor Blockers
Scopolamine (2. 0 microg)

Sodium Channel Blockers
TTX (Tetrodotoxin, 10 ng) (blocks APs through membrane stabilisation)